Develops treatments for rare kidney diseases, focusing on improving the lives of patients with chronic kidney conditions.
Calliditas Therapeutics AB (publ) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of pharmaceutical products targeting orphan indications, with a primary focus on renal and hepatic diseases. The company's flagship product, Nefecon, is an oral formulation of budesonide, an immunosuppressant used in the treatment of immunoglobulin A nephropathy, an autoimmune renal disease.
Calliditas Therapeutics' lead product candidate, Setanaxib, is a NOX inhibitor currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Setanaxib is also being investigated in Phase 2 trials for squamous cell carcinoma of the head and neck cancer, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, the company is developing Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis, further expanding its therapeutic portfolio.
Established in 20004 and headquartered in Stockholm, Sweden, Calliditas Therapeutics continues to advance its pipeline of innovative therapies aimed at addressing unmet medical needs in niche patient populations. With a commitment to scientific excellence and patient-centric research, the company strives to bring effective treatments to market that improve the quality of life for patients suffering from challenging renal and hepatic conditions.